Riemann, Donatus

[["dc.bibliographiccitation.issue","136"],["dc.bibliographiccitation.journal","Journal of Visualized Experiments"],["dc.contributor.author","Riemann, Donatus"],["dc.contributor.author","Petkova, Andoniya"],["dc.contributor.author","Dresbach, Thomas"],["dc.contributor.author","Wallrafen, Rebecca"],["dc.date.accessioned","2020-12-10T18:47:29Z"],["dc.date.available","2020-12-10T18:47:29Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.3791/58043"],["dc.identifier.eissn","1940-087X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78783"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","An Optical Assay for Synaptic Vesicle Recycling in Cultured Neurons Overexpressing Presynaptic Proteins"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","453"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","The Journal of Clinical Psychiatry"],["dc.bibliographiccitation.lastpage","463"],["dc.bibliographiccitation.volume","62"],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Voderholzer, U."],["dc.contributor.author","Riemann, D."],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Hohagen, F."],["dc.contributor.author","Berger, M."],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T09:00:49Z"],["dc.date.available","2018-11-07T09:00:49Z"],["dc.date.issued","2001"],["dc.description.abstract","Background: Over recent years, the use of antidepressants for the symptomatic treatment of insomnia has grown substantially, but controlled studies are still lacking. Our study is the first investigation to prove objective efficacy and tolerability of low doses of a sedating antidepressant in a randomized, double-blind, and placebo-controlled manner in patients with primary insomnia. Method: Forty seven drug-free patients meeting DSM-IV criteria for primary insomnia (mean +/- SD duration of complaints = 11.2 +/- 9.7 years) received either 25-50 mg of the tricyclic antidepressant doxepin or placebo for 4 weeks followed by 2 weeks of placebo withdrawal. Sleep was measured by polysomnography at baseline and the first night of application, at 4 weeks of treatment and the first to third night of withdrawal, and after 2 weeks of withdrawal. Results: In the doxepin-treated patients who completed the study (N = 20, 47.6 +/- 11.3), medication significantly increased sleep efficiency after acute (night 1, p less than or equal to .001) and subchronic (night 28, p less than or equal to .05) intake compared with the patients who received placebo (N = 20, 47.4 +/- 16.8 years of age). Latency to sleep onset was not affected since the patients had normal baseline sleep latencies. Investigators found doxepin to cause significantly (P less than or equal to .05) better global improvement at the first day of treatment. Patients rated sleep quality (p less than or equal to .001) and working ability (p less than or equal to .005) to be significantly improved by doxepin during the whole treatment period. Overall rebound in sleep parameters was not observed, but patients with severe rebound insomnia were significantly more frequent in the doxepin group (night 29, p less than or equal to .01; night 30, p less than or equal to .01; night 31, p less than or equal to .05). No significant group differences in side effects were Found, but 2 doxepin-treated patients dropped out of the study due to specific side effects (increased liver enzymes, leukopenia, and thrombopenia). Conclusion: The results support the effectiveness of low doses of doxepin to improve sleep and working ability in chronic primary insomniacs, although subjective effects were light to moderate, and in some patients, rebound insomnia and specific side effects have to be considered."],["dc.identifier.isi","000169918900009"],["dc.identifier.pmid","11465523"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24262"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Physicians Postgraduate Press"],["dc.relation.issn","0160-6689"],["dc.title","Doxepin in the treatment of primary insomnia: A placebo-controlled, double-blind, polysomnographic study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","99"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.bibliographiccitation.lastpage","104"],["dc.bibliographiccitation.volume","252"],["dc.contributor.author","Backhaus, J."],["dc.contributor.author","Junghanns, K."],["dc.contributor.author","Mueller-Popkes, K."],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Riemann, D."],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Hohagen, F."],["dc.date.accessioned","2018-11-07T10:27:39Z"],["dc.date.available","2018-11-07T10:27:39Z"],["dc.date.issued","2002"],["dc.description.abstract","objective To evaluate the effect of short-term training of general practitioners (GPs) on their diagnosis and treatment of chronic insomnia. Methods A three-step randomized control group design was used: After baseline evaluation (T1) a group of 9 GPs underwent a training of half a day, while 7 GPs served as a control group. The diagnostic and therapeutic handling of insomnia patients was reevaluated under obligatory use of a structured diagnostic questionnaire (T2) and under optional use of it (T3). Results From 16 general practices, 4,754 patients were included. The frequency rate of insomnia was 19.3%. The lowest diagnostic and treatment rate was found for insomnia patients without comorbidity (15% at T1). Systematic non-pharmacological treatment was not offered by the GPs. At T2 the diagnosis rate increased significantly from 37.9% (T1) to 71.5% (T2, p = 0.038). It fell back to lower levels at T3 but remained better than at T1. At T3 non-pharmacological treatments and referral to a sleep expert were advised more often. Conclusion Short-term training of GPs can significantly improve their diagnostic sensitivity and first-line treatment efforts against insomnia."],["dc.identifier.doi","10.1007/s00406-002-0361-x"],["dc.identifier.isi","000177405500001"],["dc.identifier.pmid","12192465"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43272"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0940-1334"],["dc.title","Short-term training increases diagnostic and treatment rate for insomnia in general practice"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","165"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.lastpage","174"],["dc.bibliographiccitation.volume","35"],["dc.contributor.author","Riemann, D."],["dc.contributor.author","Voderholzer, U."],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Wiegand, M. H."],["dc.contributor.author","Laakmann, G."],["dc.contributor.author","Baghai, T."],["dc.contributor.author","Fischer, W."],["dc.contributor.author","Hoffmann, M."],["dc.contributor.author","Hohagen, F."],["dc.contributor.author","Mayer, G."],["dc.contributor.author","Berger, M."],["dc.date.accessioned","2018-11-07T10:08:19Z"],["dc.date.available","2018-11-07T10:08:19Z"],["dc.date.issued","2002"],["dc.description.abstract","In recent years, sedating antidepressants have been increasingly used to treat primary insomnia. Up to now, only one open pilot study with trimipramine and one double-blind placebo-controlled study with doxepin have leant scientific support for this approach in treating primary insomnia. In order to test the hypothesis that sedating antidepressants are useful in the treatment of primary insomnia, the effect of trimipramine on objectively and subjectively measured parameters of sleep was investigated in a double-blind placebo- and lormetazepam-controlled study in a sample of 55 patients with primary insomnia attending outpatient sleep-disorder clinics. Trimipramine was selected since it has shown positive effects on sleep continuity with a lack of REM sleep suppression in studies on depressed patients and in one pilot study on patients with primary insomnia. Trimipramine at an average dose of 100 mg over a period of 4 weeks significantly enhanced sleep efficiency, but not total sleep time (which had been the primary target variable) compared to placebo as measured by polysomnography. Changes in objective sleep parameters were paralleled by changes in subjective sleep parameters. Trimipramine did not suppress REM sleep. Lormetazepam decreased wake time and sleep stage 3 and increased REM sleep compared to placebo. After switching trimipramine to placebo, sleep parameters returned to baseline. There was no evidence of any rebound effect from trimipramine. Side effects from trimipramine were only marginal. This first double-blind placebo-controlled study with trimipramine suggests its efficacy in the treatment of primary insomnia. However, due to the large intra- and interindividual variance in the parameters of interest before and during treatment a larger sample size would have been necessary to strengthen the validity of our findings."],["dc.identifier.doi","10.1055/s-2002-34119"],["dc.identifier.isi","000178383500002"],["dc.identifier.pmid","12237787"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39450"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0176-3679"],["dc.title","Trimipramine in primary insomnia: Results of a polysomnographic double-blind controlled study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","PII S0165-1781(02)00249-4"],["dc.bibliographiccitation.firstpage","17"],["dc.bibliographiccitation.issue","1-2"],["dc.bibliographiccitation.journal","Psychiatry Research"],["dc.bibliographiccitation.lastpage","27"],["dc.bibliographiccitation.volume","113"],["dc.contributor.author","Riemann, D."],["dc.contributor.author","Klein, T."],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Feige, B."],["dc.contributor.author","Horny, A."],["dc.contributor.author","Hummel, R."],["dc.contributor.author","Weske, G."],["dc.contributor.author","Al-Shajlawi, A."],["dc.contributor.author","Voderholzer, U."],["dc.date.accessioned","2018-11-07T09:42:15Z"],["dc.date.available","2018-11-07T09:42:15Z"],["dc.date.issued","2002"],["dc.description.abstract","The present study investigated evening and nocturnal serum cortisol and melatonin concentrations in patients with primary insomnia to test if this clinical condition is accompanied by an increase of cortisol secretion and a simultaneous decrease of nocturnal melatonin production. Ten drug-free patients (4 males, 6 females) with primary insomnia (mean age +/- S.D.: 39.2 +/- 9.1 years) and 10 age- and gender-matched healthy controls participated in the study. All subjects spent three consecutive nights in the sleep laboratory with polysomnography. Measurement of cortisol and melatonin (from 19:00 h to 09:00 h) was performed prior to and during the last laboratory night. Contrary to expectation. cortisol secretion did not differ between healthy controls and insomniac patients. On the other hand, nocturnal melatonin production was significantly diminished in insomniac patients. Polysomnographically determined sleep patterns. in contrast to subjective ratings of sleep, demonstrated only minor alterations of sleep in the insomniac group. The lack of increased cortisol secretion in the patients with primary insomnia indicates that results from studies on the biological consequences of experimental sleep loss in healthy subjects cannot be applied to primary insomnia in general, especially if there are only minor objective sleep alterations. In spite of the negligible objective sleep disturbances in the present sample, nocturnal melatonin production was reduced, which tentatively suggests a role for this hormone in primary insomniacs. The pathophysiological significance of this finding is, however, still a matter of debate. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/S0165-1781(02)00249-4"],["dc.identifier.isi","000179989900002"],["dc.identifier.pmid","12467942"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33914"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Sci Ireland Ltd"],["dc.relation.issn","0165-1781"],["dc.title","Nocturnal cortisol and melatonin secretion in primary insomnia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","MMW-FORTSCHRITTE DER MEDIZIN"],["dc.bibliographiccitation.lastpage","4"],["dc.contributor.author","Wittchen, Hans-Ulrich"],["dc.contributor.author","Linden, M."],["dc.contributor.author","Schwarzer, W."],["dc.contributor.author","Riemann, D."],["dc.contributor.author","Boerner, Reinhard Joachim"],["dc.contributor.author","Bandelow, Borwin"],["dc.date.accessioned","2018-11-07T08:58:12Z"],["dc.date.available","2018-11-07T08:58:12Z"],["dc.date.issued","2001"],["dc.description.abstract","In the past Generalized anxiety disorder (GAD) - previously classified as anxiety neurosis - was regarded as not being a separate diagnostic entity. On the basis of new explicit criteria for GAD in the 90ies, GAD-specific pharmacological (i.e. SNRI) and psychological treatments with improved efficacy have become available. The Generalized Anxiety and Depression in Primary care study (GAD-P) investigates the prevalence of GAD in primary care settings and evaluates the patterns of care provided. Aims, methods and findings of the GAD-P study are described in this supplement."],["dc.identifier.isi","000170082600001"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23584"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.relation.issn","1438-3276"],["dc.title","Generalized anxiety disorders - A neglected illness? Background and aims of the GAD-P-Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","15791"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Riemann, Donatus"],["dc.contributor.author","Wallrafen, Rebecca"],["dc.contributor.author","Dresbach, Thomas"],["dc.date.accessioned","2018-10-10T08:59:42Z"],["dc.date.available","2018-10-10T08:59:42Z"],["dc.date.issued","2017-11-17"],["dc.description.abstract","Mutations in the human homolog of the Drosophila gene Rogdi cause Kohlschütter-Tönz syndrome. This disorder is characterised by amelogenesis imperfecta, as well as severe neurological symptoms including epilepsy and psychomotor delay. However, little is known about the protein encoded by Rogdi, and hence the pathogenic mechanisms underlying Kohlschütter-Tönz syndrome have remained elusive. Using immunofluorescence of rat cultured hippocampal neurons and brain sections we find that Rogdi is enriched at synaptic sites. In addition, recombinant GFP-Rogdi expressed in cultured neurons was efficiently targeted to presynaptic sites, where it colocalised with the presynaptic scaffolding protein Bassoon and the synaptic vesicle markers Synaptophysin, Synapsin-1, VAMP2/Synaptobrevin and Mover. Our data indicate that GFP-Rogdi harbours efficient signals for presynaptic targeting, and that Rogdi is a presynaptic protein. Thus, the neurological symptoms associated with Kohlschütter-Tönz syndrome may arise from presynaptic dysfunction."],["dc.fs.pkfprnr","69207"],["dc.identifier.doi","10.1038/s41598-017-16004-1"],["dc.identifier.fs","633270"],["dc.identifier.pmid","29150638"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14859"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/15926"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.relation.eissn","2045-2322"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","The Kohlschütter-Tönz syndrome associated gene Rogdi encodes a novel presynaptic protein"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","4"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","NERVENHEILKUNDE"],["dc.bibliographiccitation.lastpage","16"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Wittchen, Hans-Ulrich"],["dc.contributor.author","Krause, Petra"],["dc.contributor.author","Hofler, M."],["dc.contributor.author","Winter, S."],["dc.contributor.author","Spiegel, B."],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Riemann, D."],["dc.contributor.author","Pittrow, David"],["dc.contributor.author","Steiger, A."],["dc.contributor.author","Pfister, H."],["dc.date.accessioned","2018-11-07T09:36:55Z"],["dc.date.available","2018-11-07T09:36:55Z"],["dc.date.issued","2001"],["dc.description.abstract","Aim: To estimate the point prevalence of insomnia and other sleep disorders in primary care, by severity and impairments and doctor's recognition rates. Methods: Nationwide sample of 539 primary care settings along with their characterization. Standardized assessment of all attenders and the doctors (N = 19155 patients) on the NISAS target day using a sleep questionnaire (PSQI) and additional questions to cover psychosocial and additional clinical variables were conducted including a CGI-rating. Results: 1. Despite of only moderate self-rated competence with regard to recognition, diagnosis and treatment doctors in the prestudy indicated to primarily treat patients themselves, despite of substantial burden and time investment. 2. The patient sample could be regarded as typical. 3. Sleep complaints were found to be overall the 3rd most frequent reason. Almost every second patient on the assessment day indicated to suffer from sleep complaints. 26.5% fulfilled study criteria (DSM-IV) for insomnia (prevalence 16-19 years old: 17.5%, 80+ years old: 31.9%). Other sleep disorders were frequently comorbid with insomnia. 4. Doctors themselves using the CGI rated 46.4% of all primary care patients as having a sleep disorder, 85.6% of which were rated as chronic. Primary core doctors prevalence rate for insomnia was 25.9%. Only 54.3% of all patients were correctly diagnosed as insomnia by the doctor. Discussion: NISAS provides for the first time nationally representative estimates of sleep complaints and disorders according to severity, correlates and recognition in primary core. The high prevalence and the associated burden for primary care is highlighted along with the high degree of chronicity and partly marked deficits in recognition and diagnosis."],["dc.identifier.isi","000167295800002"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32721"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","F K Schattauer Verlag Gmbh"],["dc.relation.issn","0722-1541"],["dc.title","The Nationwide Insomnia Screening and Awareness Study (NISAS) 2000"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]